SOURCE: MMIT Analytics, as of 11/26/19
Thursday, December 5, 2019
The FDA in recent weeks approved...
...two new sickle cell disease
therapies with potential to reshape the market basket, Global Blood
Therapeutics' Oxbryta, a once-daily pill, and Novartis' Adakveo, a monthly
infusion. In the pharmacy benefit, the most advantaged therapy for the
treatment of sickle cell disease is currently Bristol-Meyers Squibb's Droxia,
which holds preferred formulary status for 44% of covered lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment